Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2025)

Crinetics Pharmaceuticals has reported EBITDA Margin over the past 9 years, most recently at 1998.77% for Q4 2025.

  • Quarterly results put EBITDA Margin at 1998.77% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 6034.5% (up 2268754.0% YoY), and the annual figure for FY2025 was 6034.5%, up 2268754.0%.
  • EBITDA Margin for Q4 2025 was 1998.77% at Crinetics Pharmaceuticals, up from 90572.03% in the prior quarter.
  • Over the last five years, EBITDA Margin for CRNX hit a ceiling of 1163.75% in Q1 2022 and a floor of 90572.03% in Q3 2025.
  • Median EBITDA Margin over the past 5 years was 9717.66% (2022), compared with a mean of 15168.89%.
  • Peak annual rise in EBITDA Margin hit 739241bps in 2025, while the deepest fall reached -1593236bps in 2025.
  • Crinetics Pharmaceuticals' EBITDA Margin stood at 2890.91% in 2021, then plummeted by -114bps to 6193.51% in 2022, then tumbled by -164bps to 16363.58% in 2023, then decreased by -14bps to 18645.36% in 2024, then soared by 89bps to 1998.77% in 2025.
  • The last three reported values for EBITDA Margin were 1998.77% (Q4 2025), 90572.03% (Q3 2025), and 11252.96% (Q2 2025) per Business Quant data.